AKERO THERAPEUTICS INC's ticker is AKRO and the CUSIP is 00973Y108. A total of 175 filers reported holding AKERO THERAPEUTICS INC in Q1 2024. The put-call ratio across all filers is 1.31 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $466 | -4.5% | 20,000 | 0.0% | 0.00% | 0.0% |
| Q1 2024 | $488 | -25.9% | 20,000 | -27.5% | 0.00% | 0.0% |
| Q4 2023 | $659 | -50.5% | 27,600 | 0.0% | 0.00% | -66.7% |
| Q3 2023 | $1,332 | +37.9% | 27,600 | +27.8% | 0.00% | +50.0% |
| Q2 2023 | $966 | +19.0% | 21,600 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $812 | +8.7% | 21,600 | +54.3% | 0.00% | 0.0% |
| Q4 2022 | $747 | -99.8% | 14,000 | 0.0% | 0.00% | +100.0% |
| Q3 2022 | $417,000 | +111.7% | 14,000 | +3.7% | 0.00% | – |
| Q1 2022 | $197,000 | -24.5% | 13,500 | +9.8% | 0.00% | -100.0% |
| Q4 2021 | $261,000 | -1.9% | 12,300 | +2.5% | 0.00% | 0.0% |
| Q3 2021 | $266,000 | -12.8% | 12,000 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $305,000 | -9.8% | 12,000 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $338,000 | +12.3% | 12,000 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $301,000 | – | 12,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| University of Wisconsin Foundation | 103,816 | $5,251,013 | 6.02% |
| Boxer Capital, LLC | 1,676,733 | $84,809,155 | 4.52% |
| Redmile Group, LLC | 1,769,684 | $89,510,617 | 4.26% |
| Ghost Tree Capital, LLC | 250,000 | $12,645,000 | 4.16% |
| Logos Global Management LP | 600,000 | $30,348,000 | 4.05% |
| COMMODORE CAPITAL LP | 565,000 | $28,577,700 | 3.34% |
| Yiheng Capital Management, L.P. | 1,221,674 | $61,792,271 | 3.15% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 200,000 | $10,116,000 | 3.07% |
| Atlas Venture Life Science Advisors, LLC | 359,251 | $18,170,915 | 2.81% |
| Perceptive Advisors | 1,619,425 | $81,910,517 | 2.73% |